Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

2.9%

1 terminated/withdrawn out of 35 trials

Success Rate

97.1%

+10.6% vs industry average

Late-Stage Pipeline

37%

13 trials in Phase 3/4

Results Transparency

82%

27 of 33 completed trials have results

Key Signals

1 recruiting27 with results

Enrollment Performance

Analytics

Phase 2
19(54.3%)
Phase 3
13(37.1%)
Phase 1
3(8.6%)
35Total
Phase 2(19)
Phase 3(13)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (35)

Showing 20 of 35 trials
NCT05392179Phase 2Completed

A Study in Subjects With Retinitis Pigmentosa

Role: lead

NCT07402876Phase 3Recruiting

A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

Role: lead

NCT06493604Phase 3Completed

A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Role: lead

NCT06685692Phase 2Completed

A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)

Role: lead

NCT04735393Phase 3Completed

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Role: lead

NCT06424444Phase 3Completed

A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Role: lead

NCT04136366Phase 3Completed

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

Role: lead

NCT06389214Phase 3Completed

A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease

Role: lead

NCT03660878Phase 1Completed

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Role: lead

NCT04674358Phase 2Completed

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Role: lead

NCT05062330Phase 3Completed

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Role: lead

NCT04908514Phase 2Completed

A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

Role: lead

NCT03916042Phase 2Completed

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Role: lead

NCT05102409Phase 2Completed

An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber

Role: lead

NCT05392192Phase 2Completed

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Role: lead

NCT05487404Phase 1Completed

A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels

Role: lead

NCT03709121Phase 1Completed

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Role: lead

NCT04971031Phase 2Completed

A Clinical Trial to Assess Subjects With Dry Eye Disease.

Role: lead

NCT04847544Phase 2Completed

A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

Role: lead

NCT04728711Phase 2Completed

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

Role: lead